In most patients, trastuzumab-associated cardiotoxicity is reversible; there is complete recovery of cardiac function after treatment discontinuation. In contrast, chronic anthracycline-associated cardiotoxicity may not be reversible after treatment discontinuation due to myocyte necrosis, destruction, and replacement by fibrous tissue.